Detalles de la búsqueda
1.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
N Engl J Med;
384(12): 1101-1112, 2021 03 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33761207
2.
Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis.
J Allergy Clin Immunol;
150(4): 882-893, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35568077
3.
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
J Am Acad Dermatol;
87(4): 815-824, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35863467
4.
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies.
Acta Derm Venereol;
101(2): adv00402, 2021 Feb 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33491094
5.
Dupilumab in Chronic Actinic Dermatitis: a retrospective case series.
Br J Dermatol;
2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38656979
6.
Neutropenia in patients on dupilumab for atopic dermatitis: a case series and review of trial data.
Br J Dermatol;
188(6): 803-805, 2023 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36930577
7.
Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic.
Br J Dermatol;
188(4): 471-473, 2023 03 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36715624
8.
English Sunday lunch dermatitis: Allergic contact dermatitis to parsnip, carrot, fennel (and ivy).
Contact Dermatitis;
83(4): 317-318, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32383193
9.
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis.
Am J Hum Genet;
89(3): 432-7, 2011 Sep 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-21839423
10.
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Dermatol Ther (Heidelb);
14(5): 1127-1144, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696027
11.
Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.
Cornea;
42(4): 507-519, 2023 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525340
12.
Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.
Dermatol Ther (Heidelb);
13(9): 1893-1907, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37482564
13.
Characterization of a Musculoskeletal Syndrome of Enthesitis and Arthritis in Patients With Atopic Dermatitis Treated With Dupilumab, an Interleukin-4/13 Inhibitor.
Arthritis Rheumatol;
75(10): 1793-1797, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163452
14.
Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience.
J Invest Dermatol;
143(9): 1708-1716.e4, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36889663
15.
Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey).
Dermatol Ther (Heidelb);
13(4): 961-980, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36922463
16.
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
Am J Clin Dermatol;
24(6): 939-952, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37682422
17.
Long-term topical management of psoriasis: the road ahead.
J Dermatolog Treat;
33(1): 111-120, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32091278
18.
Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7
Eur J Dermatol;
32(2): 237-243, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35866910
19.
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
J Allergy Clin Immunol Pract;
10(12): 3228-3237.e2, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108923
20.
Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD).
J Dermatolog Treat;
33(5): 2565-2570, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35255779